As of 2025-07-12, the Intrinsic Value of NextCure Inc (NXTC) is -8.91 USD. This NXTC valuation is based on the model Peter Lynch Fair Value. With the current market price of 0.40 USD, the upside of NextCure Inc is -2,356.37%.
Based on its market price of 0.40 USD and our intrinsic valuation, NextCure Inc (NXTC) is overvalued by 2,356.37%.
Note: result may not be accurate due to the invalid valuation result of Peter Lynch's fair value model.
| Range | Selected | Upside | |
| a | |||
| Fair Value | -8.91 - -8.91 | -8.91 | -2,356.37% |
| P/E | (31.80) - (43.07) | (38.77) | -9915.2% |
| DDM - Stable | (11.62) - (42.78) | (27.20) | -6985.9% |
| DDM - Multi | (11.02) - (33.54) | (16.82) | -4358.6% |
| Market Cap (mil) | 11.08 |
| Beta | 0.34 |
| Outstanding shares (mil) | 28.05 |
| Enterprise Value (mil) | -10.75 |
| Market risk premium | 4.60% |
| Cost of Equity | 11.24% |
| Cost of Debt | 5.00% |
| WACC | 7.46% |